Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Poliomyelitis Pipeline Drugs Market Report Overview

Polio is a highly infectious disease caused by a virus. It invades the nervous system and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

The Poliomyelitis pipeline drugs market research report provides comprehensive information on the Poliomyelitis targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Poliomyelitis targeted therapeutics development with respective active and dormant or discontinued projects.

Poliomyelitis Pipeline Drugs Market Segmentation by Target

The key targets in the Poliomyelitis pipeline drugs market are Diphtheria Toxin, Pertussis Toxin, Tetanus Toxin, Haemophilus influenzae Lipooligosaccharide, and Toll Like Receptor 5. Diphtheria Toxin, Pertussis Toxin, and Tetanus Toxin accounted for the highest number of Poliomyelitis pipeline drugs in development in 2022.

Poliomyelitis Pipeline Drugs Market Analysis, by Target

Poliomyelitis Pipeline Drugs Market Analysis, by TargetFor more target insights on the Poliomyelitis pipeline drugs market, download a free report sample

Poliomyelitis Pipeline Drugs Market Segmentation by Mechanism of Action

The key mechanism of action of the Poliomyelitis pipeline drugs market is Toll Like Receptor 5 Agonist.

Poliomyelitis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Poliomyelitis pipeline drugs market are intramuscular, oral, subcutaneous, intradermal, intravenous, parenteral, and transdermal. Intramuscular is the most preferred RoA in the Poliomyelitis pipeline drugs market in 2022.

Poliomyelitis Pipeline Drugs Market Analysis, by Routes of Administration

Poliomyelitis Pipeline Drugs Market Analysis, by Routes of AdministrationFor more RoA insights on the Poliomyelitis pipeline drugs market, download a free report sample

Poliomyelitis Pipeline Drugs Market Segmentation by Molecule Types

Some of the key molecule types in the Poliomyelitis pipeline drugs market are inactivated vaccine, live attenuated vaccine, toxoid vaccine, subunit vaccine, conjugate vaccine, and vaccine. Inactivated vaccine led the Poliomyelitis pipeline drugs market in terms of molecule types.

Poliomyelitis Pipeline Drugs Market Analysis, by Molecule Types

Poliomyelitis Pipeline Drugs Market Analysis, by Molecule TypesTo know more about molecule types in the Poliomyelitis pipeline drugs market, download a free report sample

Poliomyelitis Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Poliomyelitis pipeline drugs market are Biological E Ltd, KM Biologics Co Ltd, Beijing Minhai Biotechnology Co Ltd, LG Chem Ltd, Panacea Biotec Ltd, and Serum Institute of India Pvt Ltd among others.

Poliomyelitis Pipeline Drugs Market Analysis, by Companies

Poliomyelitis Pipeline Drugs Market Analysis, by CompaniesTo know more about the leading Poliomyelitis pipeline drugs market players, download a free report sample

Poliomyelitis Pipeline Drugs Market Overview

Key Target Diphtheria Toxin, Pertussis Toxin, Tetanus Toxin, Haemophilus influenzae Lipooligosaccharide, and Toll Like Receptor 5
Key Mechanism of Action Toll Like Receptor 5 Agonist
Key Routes of Administration Intramuscular Oral, Subcutaneous, Intradermal, Intravenous, Parenteral, and Transdermal
Key Molecule Types Inactivated Vaccine, Live Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine, and Vaccine
Leading Companies Biological E Ltd, KM Biologics Co Ltd, Beijing Minhai Biotechnology Co Ltd, LG Chem Ltd, Panacea Biotec Ltd, and Serum Institute of India Pvt Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Beijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Bharat Biotech Ltd
Biken Co Ltd
Biological E Ltd
Biological Mimetics Inc
Boryung Pharmaceutical Co Ltd
CanSino Biologics Inc
Grifols SA
Helix Biogen Institute
Intravacc BV
Johnson & Johnson
KM Biologics Co Ltd
LG Chem Ltd
Micron Biomedical Inc
Nanolek
Panacea Biotec Ltd
Serum Institute of India Pvt Ltd
Shantha Biotechnics Pvt Ltd
Statera Biopharma Inc
Vaxxas Inc
Wuhan Institute of Biological Products Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Poliomyelitis – Overview

Poliomyelitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Poliomyelitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Poliomyelitis – Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Beijing Tiantan Biological Products Co Ltd

Bharat Biotech Ltd

Biken Co Ltd

Biological E Ltd

Biological Mimetics Inc

Boryung Pharmaceutical Co Ltd

CanSino Biologics Inc

Grifols SA

Helix Biogen Institute

Intravacc BV

Johnson & Johnson

KM Biologics Co Ltd

LG Chem Ltd

Micron Biomedical Inc

Nanolek

Panacea Biotec Ltd

Serum Institute of India Pvt Ltd

Shantha Biotechnics Pvt Ltd

Statera Biopharma Inc

Vaxxas Inc

Wuhan Institute of Biological Products Co Ltd

Poliomyelitis – Drug Profiles

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine – Drug Profile

Product Description

Mechanism Of Action

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine – Drug Profile

Product Description

Mechanism Of Action

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile

Product Description

Mechanism Of Action

BK-1310 – Drug Profile

Product Description

Mechanism Of Action

CSB-017 – Drug Profile

Product Description

Mechanism Of Action

immune globulin (human) – Drug Profile

Product Description

Mechanism Of Action

JNJ-2348 – Drug Profile

Product Description

Mechanism Of Action

KD-2396 – Drug Profile

Product Description

Mechanism Of Action

KD-370 – Drug Profile

Product Description

Mechanism Of Action

LBVC – Drug Profile

Product Description

Mechanism Of Action

LBVD – Drug Profile

Product Description

Mechanism Of Action

polio (trivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [serotype 1] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [serotype 2] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [serotype 2] vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

polio [serotype 3] (monovalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [serotype 3] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [serotype 3] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [serotypes 1, 2, 3] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [strain Sabin] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [strain Sabin] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [strain Sabin] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio [strain Sabin] vaccine – Drug Profile

Product Description

Mechanism Of Action

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

polio vaccine 2 – Drug Profile

Product Description

Mechanism Of Action

poliomyelitis (trivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

poliomyelitis [sabin] (vero cell) vaccine – Drug Profile

Product Description

Mechanism Of Action

poliomyelitis [serotype PV3] (virus like particles) vaccine – Drug Profile

Product Description

Mechanism Of Action

poliomyelitis vaccine – Drug Profile

Product Description

Mechanism Of Action

poliomyelitis vaccine – Drug Profile

Product Description

Mechanism Of Action

poliomyelitis vaccine + rotavirus vaccine – Drug Profile

Product Description

Mechanism Of Action

SA-702 – Drug Profile

Product Description

Mechanism Of Action

Poliomyelitis – Dormant Projects

Poliomyelitis – Discontinued Products

Poliomyelitis – Product Development Milestones

Featured News & Press Releases

Jun 09, 2022: Sinovac Biotech receives WHO prequalification for polio vaccine

Apr 12, 2022: Pertussis, Diphtheria, Tetanus, Polio, Hib vaccine filed in Japan: BIKEN/Mitsubishi

Apr 11, 2022: Notification of manufacturing and marketing approval application for pertussis/diphtheria/tetanus/inactivated polio/Hib combined vaccine (BK1310/MT-2355)

Apr 11, 2022: Marketing authorization application of pertussis, diphtheria, tetanus, inactivated polio and Hib combined vaccine (BK1310/MT-2355)

Jul 20, 2021: Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China

Dec 09, 2020: New polio vaccine against strain that threatens eradication is safe and generates immune response in adults, young children, and infants

Apr 23, 2020: AJ Vaccines secures WHO Prequalification for polio vaccine Picovax

Apr 16, 2019: Sinovac announces positive results from Phase III trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) published in the journal of Infectiou

Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development

May 21, 2018: A single-injection vaccine for the polio virus

Apr 19, 2018: Sinovac Announces Preliminary Results of Phase III Trial on sIPV

Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate

Sep 16, 2014: Vaxxas initiates research project on advancing next generation technology for polio vaccine delivery

Oct 31, 2012: Statens Serum Institut receives a grant of $158,739 from Bill & Melinda Gates Foundation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Poliomyelitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Poliomyelitis – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022

Poliomyelitis – Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022

Poliomyelitis – Pipeline by Bharat Biotech Ltd, 2022

Poliomyelitis – Pipeline by Biken Co Ltd, 2022

Poliomyelitis – Pipeline by Biological E Ltd, 2022

Poliomyelitis – Pipeline by Biological Mimetics Inc, 2022

Poliomyelitis – Pipeline by Boryung Pharmaceutical Co Ltd, 2022

Poliomyelitis – Pipeline by CanSino Biologics Inc, 2022

Poliomyelitis – Pipeline by Grifols SA, 2022

Poliomyelitis – Pipeline by Helix Biogen Institute, 2022

Poliomyelitis – Pipeline by Intravacc BV, 2022

Poliomyelitis – Pipeline by Johnson & Johnson, 2022

Poliomyelitis – Pipeline by KM Biologics Co Ltd, 2022

Poliomyelitis – Pipeline by LG Chem Ltd, 2022

Poliomyelitis – Pipeline by Micron Biomedical Inc, 2022

Poliomyelitis – Pipeline by Nanolek, 2022

Poliomyelitis – Pipeline by Panacea Biotec Ltd, 2022

Poliomyelitis – Pipeline by Serum Institute of India Pvt Ltd, 2022

Poliomyelitis – Pipeline by Shantha Biotechnics Pvt Ltd, 2022

Poliomyelitis – Pipeline by Statera Biopharma Inc, 2022

Poliomyelitis – Pipeline by Vaxxas Inc, 2022

Poliomyelitis – Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022

Poliomyelitis – Dormant Projects, 2022

Poliomyelitis – Dormant Projects, 2022 (Contd..1)

Poliomyelitis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Poliomyelitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.